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The metabolic syndrome – What is it
and how should it be managed?
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Abstract
A cluster of metabolic factors have been merged into an entity named the metabolic syndrome. Although the charac-
teristics of this syndrome have varied over time the presently used definition was established in 2009. The presence of
three abnormal findings out of five components qualifies a person for the metabolic syndrome: elevated waist circum-
ference, elevated triglycerides, reduced high-density lipoprotein cholesterol, elevated blood pressure and elevated fasting
plasma glucose. Cut points have been defined for all components apart from waist circumference, for which national or
regional values are used. The metabolic syndrome predicts cardiovascular disease and type 2 diabetes. This associated
risk does not exceed its components whereof elevated blood pressure is the most frequent. A successful management
should, however, address all factors involved. The management is always based on healthy lifestyle choices but has not
infrequently to be supported by pharmacological treatment, especially blood pressure lowering drugs. The metabolic
syndrome is a useful example of the importance of multiple targets for preventive interventions. To be successful
management has to be individualized not the least when it comes to pharmacological therapy. Frail elderly people
should not be over-treated. Knowledge transfer of how risk factors act should be accompanied by continuous trust
building and motivation. In complex situations with a mix of biological risk factors, adverse social conditions and
unhealthy lifestyle, everything cannot be changed at once. It is better to aim for small steps that are lasting than
large, unsustainable steps with relapses to unhealthy behaviours. A person with the metabolic syndrome will always
be afflicted by its components, which is the reason that management has to be sustained over a very long time. This
review summarizes the knowledge on the metabolic syndrome and its management according to present state of the art.
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Introduction
The word ‘syndrome’ originates from the Greek
‘s0ndroon’, with the meaning ‘coexistence’. In the
medical context it is used to describe a cluster of signs
and symptoms that in one way or another are related to
a certain disease.1 Sometimes the term ‘syndrome’ may
be so closely connected to the pathophysiological pro-
cess behind a disease that it is diﬃcult to separate the
two from each other, syndrome and disease, and an
example may be Down’s syndrome. More commonly,
however, a syndrome indicates that certain clinical ﬁnd-
ings co-exist more frequently than would be expected if
it was just a play of chance and that this accumulation
is of clinical relevance. Still, the cause may often be
uncertain. The metabolic syndrome represents such an
entity and its presence signals that a person with this
syndrome is at an increased risk for developing type 2
diabetes (T2D) and cardiovascular disease in the future
and that such a dismal outcome may be counteracted
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by managing the components of the metabolic syn-
drome by means of appropriate measures.2
The objective of this review is to (1) give an historical
background to the metabolic syndrome, (2) describe
how its components were harmonized in 2009,
(3) report on the clinical implications of the syndrome,
and (4) review how the syndrome should be managed
according to the state of the clinical art in 2019.
Historical background to the
metabolic syndrome
Various diagnostic criteria have been proposed by dif-
ferent people and organizations over the past decades.
In 1923 the Swedish physician Kylin published a scien-
tiﬁc article in which he described a cluster of hyperur-
icaemia, hyperglycaemia and hypertension.3 His
observation was, however, not followed up. In 1947
the French physician Vague outlined two diﬀerent
types of obesity: abdominal adiposity (masculine type)
and lower body adiposity (female type). He emphasized
that it is abdominal adiposity that was associated with
cardiovascular disease and T2D.4 A further character-
ization was brought forward by Reaven in his Banting
lecture in 1988 in which the cluster was considered
related to insulin resistance; he labelled the cluster ‘syn-
drome X’.5 Kaplan called this combination of obesity,
non-insulin-dependent diabetes mellitus, hypertension
and dyslipidaemia ‘the deadly quartet’.6
Since then, the syndrome evolved with diﬀerent com-
binations of factors proposed to be included until in
1999 the World Health Organization (WHO)
Consultation Group launched a deﬁnition based on
central obesity combined with a cluster of metabolic
abnormalities.7 Insulin resistance was underlined as
the major underlying risk factor and evidence of insulin
resistance was required for the diagnosis. Thus, a diag-
nosis of the metabolic syndrome by WHO criteria
necessitated markers of insulin resistance plus two add-
itional risk factors, including obesity, hyperglycaemia,
hypertension, high serum triglycerides, reduced serum
high-density lipoprotein (HDL) cholesterol or microal-
buminuria. Interestingly, people with T2D were not
excluded from the deﬁnition but were considered as
having elevated glucose concentration. Soon, several
other deﬁnitions of the metabolic syndrome were pub-
lished (Table 1).
The International Diabetes Federation (IDF)
dropped the need for veriﬁed insulin resistance and
made abdominal obesity necessary as one of ﬁve factors
required for the diagnosis. Waist measurement was
emphasized as a simple screening tool.9 In 2001 in the
United States the National Cholesterol Education
Program Adult Treatment Panel III (ATP III) pro-
posed its criteria, without a requirement of insulin
resistance. The ATP III criteria used higher cut-points
for waist circumference than other deﬁnitions in order
to be consistent with the deﬁnitions of abdominal obes-
ity by the National Institutes of Health (NIH) obesity
guidelines.10
Researchers tried to agree upon a deﬁnition of the
syndrome, its components and name, but this work just
led to a plethora of publications on the epidemiology
and clinical aspects of the metabolic syndrome in dif-
ferent populations and various sub-groups. The risk
factors usually included raised blood pressure, dyslipi-
daemia (raised triglycerides and low HDL cholesterol),
raised fasting plasma glucose, raised fasting serum insu-
lin and obesity (central obesity deﬁned as a large waist
circumference or waist–hip ratio or body-mass index).
The dyslipidaemia seen in the metabolic syndrome is
characterized by large very-low-density-lipoprotein
Table 1. The ‘harmonized’ metabolic syndrome: criteria for clinical diagnosis (adapted from Borges et al.8).
Measure Categorical cut-points
Elevated waist circumference Population- and country-specific definitions
Elevated triglycerides 150mg/dL (1.7mmol/L)
Drug treatment for elevated triglycerides is an
alternative indicator
Reduced HDL cholesterol Males: <40mg/dL (1.0mmol/L)
Drug treatment for reduced
HDL-C is an alternative indicator
Females: <50mg/dL (1.3mmol/L)
Elevated blood pressure Systolic130 and/or
Antihypertensive drug treatment in patients with
a history of hypertension is an alternative indicator
Diastolic85mmHg
Elevated fasting plasma glucose 100mg/dL (5.6mmol/L)
Drug treatment of elevated glucose is an alternative
criterion
HDL-C: high-density lipoprotein cholesterol.
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particles, which initiates the generation atherogenic
remnants in the form of small dense low-density lipo-
protein and small triglyceride-rich dense high-density
lipoprotein particles, creating a highly atherogenic
lipid proﬁle.11 Other factors were proposed as well.
Hyperuricaemia, as originally pointed out by Kylin,3
may be considered a part of the syndrome, more
recently suggested also by other researchers.8
One important, albeit criticized, aspect of the meta-
bolic syndrome is that its components are all continu-
ous variables, including their associations with
cardiovascular disease and T2D. Therefore dichotomiz-
ing them for the metabolic syndrome is arbitrary,
resulting in false positives and many people being incor-
rectly labelled to be at risk of cardiovascular disease or
T2D. There are commonly agreed international,
evidence-based criteria for various risk factors. The
cut-points adopted for the metabolic syndrome were,
however, chosen for pragmatic reasons. One may also
argue that people with any component of the metabolic
syndrome are likely to beneﬁt from a healthy lifestyle
and therefore not mis-labelled.
Interestingly, Reaven critically reviewed the meta-
bolic syndrome for lack of consistency of the compo-
nents of the syndrome and their diagnostic criteria. He
proposed cut-points including the number of compo-
nents needed to make a diagnosis as suggested by dif-
ferent researchers.12 He actually asked whether there
was any reason why the metabolic syndrome should
not be given its well-deserved send-oﬀ.
The 2009 harmonization of the
metabolic syndrome
Since several deﬁnitions of the metabolic syn-
drome were proposed, it led to confusion as to how
to identify the syndrome. Some controversy also existed
about whether the metabolic syndrome is a true syn-
drome or a mixture of unrelated phenotypes.13 Whether
the metabolic syndrome fulﬁls the criteria of the true
syndrome could only be assessed by well-designed sci-
entiﬁc research. It was, however, recognized that the
proposed metabolic syndrome was not an absolute
risk indicator, because its deﬁnition did not contain
many of the factors that determine cardiovascular
risk, for example, age, sex, cigarette smoking, inﬂam-
mation, apolipoprotein B or low-density lipoprotein
cholesterol.
In 2009, representatives from IDF, American Heart
Association, NIH, International Atherosclerosis
Society, World Heart Federation and International
Association for the Study of Obesity attempted to
resolve the diﬀerences between deﬁnitions of metabolic
syndrome. They came up with a proposal called ‘har-
monizing metabolic syndrome’ with ﬁve components.13
It was agreed that none of them should be obligatory,
while three abnormal ﬁndings out of ﬁve components
would qualify a person for the metabolic syndrome as
outlined in Table 1. The cut-points were uniformly
deﬁned for all components except waist circumference,
for which national or regional cut-points can be used.
Waist measurement was suggested a useful preliminary
screening tool for the metabolic syndrome. Since ele-
vated fasting plasma glucose or drug treatment of ele-
vated glucose were included in the deﬁnition, it means
that all people with diabetes have this component.
Furthermore, since most people with T2D are obese
and many have dyslipidaemia and hypertension a
majority of them are classiﬁed as having the
metabolic syndrome. Only blood pressure and plasma
glucose cut-points were similar for both sexes, while the
other three components (elevated waist circumference,
elevated serum triglycerides and reduced HDL choles-
terol) had sex-speciﬁc cut-points.
Whether the clustering of factors that currently are
included in the metabolic syndrome really exists can be
best evaluated using epidemiological data and factor
analysis. Such an attempt was made using the
population-based data of Finnish men.14 Four factors
were identiﬁed, one of them included systolic blood
pressure, serum HDL-cholesterol and triglycerides,
body-mass index and fasting serum insulin, i.e. a cluster
of parameters indicating the metabolic syndrome.
Is there a common background for the
components of the metabolic syndrome?
In 2005, a joint statement of the American Diabetes
Association and the European Association for the
Study of Diabetes, ‘The metabolic syndrome: Time
for a critical appraisal’,15 raised several questions
regarding the syndrome. After the ‘harmonized’ deﬁn-
ition of the metabolic syndrome in 2009.1,3 Reaven in
2011 argued that little had been achieved to establish
pathophysiological understanding and clinical utility of
the metabolic syndrome despite the vast number of
published papers about this syndrome.12 Nevertheless,
there have been various attempts to propose a uniform
origin for the clustering of the components of the meta-
bolic syndrome including: (i) genetics, (ii) insulin resist-
ance, (iii) obesity, (iv) lifestyle, (v) sleep disturbances,
(vi) inﬂammation, (vii) foetal and neonatal program-
ming and (viii) disturbed circadian rhythm of body
functions, as brieﬂy discussed below.
Genetics
There are hundreds of markers in the genome that are
associated with the biological traits of the metabolic
syndrome. Genetic susceptibility may exist at various
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levels: within adipose tissue, in insulin signalling path-
ways, and in regulation of individual components of the
syndrome. No common genetic trait has, however, been
identiﬁed for the metabolic syndrome as such. Thus,
each component seems to have its own genetic back-
ground.16,17 In the Malmo¨ Preventive Project in
Sweden, 17 known genetic variants were studied in a
large cohort of individuals without diabetes followed
for 23 years. In this study, the development of the meta-
bolic syndrome was deﬁned as the development of at
least three components: obesity, dyslipidaemia, hyper-
tension and hyperglycaemia.18 None of the studied
polymorphisms was associated with more than two
components of the metabolic syndrome. Since then,
several other attempts have reached similar conclu-
sions. Many genetic variants involved in the pathogen-
esis of the metabolic syndrome are associated especially
with glucose metabolism or lipid metabolism, but there
is no uniform genetic pathogenesis for the syndrome
itself.19
Insulin resistance
Reaven stated in his Banting lecture (1988) that resist-
ance to insulin-stimulated glucose uptake and hyperin-
sulinaemia are involved in the aetiology and clinical
course of three related diseases: T2D, hypertension
and coronary artery disease.5 It was suggested that con-
sidering the acute eﬀects of insulin on sympathetic ner-
vous activity, transmembranous cation transport, renal
sodium reabsorption, cellular proliferation and lipid
metabolism, the presence of insulin resistance and/or
hyperinsulinaemia may contribute to the genesis of
obesity- and T2D-associated hypertension and possibly
also promote dyslipidaemia in these disorders.20,21
However, since identiﬁcation of insulin resistance is
complex, its interpretation challenging and its detection
in clinical settings diﬃcult, it is not possible to recom-
mend that insulin resistance be used for routine meas-
urement in clinical practice.22 The WHO (1998)
deﬁnition of the metabolic syndrome included fasting
serum insulin to be in the top 25th percentile,7 but it is
well-known that fasting serum insulin is a poor indica-
tor of insulin resistance.
Obesity
Obesity, in various forms, is associated with all other
components of the metabolic syndrome. Adipose tissue
is a major endocrine organ, secreting substances that
may play a critical role in the pathogenesis of the meta-
bolic syndrome. Abdominal obesity (usually but not
always indicated by large waist) and ectopic fat depos-
ition in the liver, pancreas and skeletal muscle seem
particularly deleterious.23 The IDF deﬁnition of the
metabolic syndrome (2005) listed a large waist circum-
ference as a requirement for the metabolic syndrome,8
but this is not included in the ‘harmonized deﬁnition’.
Nevertheless, the prevalence of abdominal obesity in
people with the metabolic syndrome is >80%,24 but
the deﬁnition of obesity in diﬀerent ethnic groups and
between sexes has been somewhat diﬃcult to deﬁne due
to diﬀerences in body frames.
Lifestyle
All components of the metabolic syndrome are asso-
ciated with some issues of lifestyle, namely, unhealthy
diet, physical inactivity and poor physical ﬁtness. In
principle the metabolic syndrome is unlikely to develop
without an unhealthy lifestyle even if there are large
variations among people with the metabolic syndrome
regarding the presence of various unhealthy habits.
Thus, it is diﬃcult to deﬁne which lifestyle habit is indi-
vidually most important. It is also diﬃcult to generalize
mechanisms of how diet, nutrients and physical activity
operate in promoting or preventing the metabolic syn-
drome. Since people’s lifestyles are related to their
socio-economic environment, many of the lifestyle
habits may have rather complex origins. There is an
inverse association between socio-economic status and
the metabolic syndrome.25 On the other hand, it has
been shown that relatively simple lifestyle intervention
programmes emphasizing a suﬃcient amount of phys-
ical activity and avoiding excess saturated fats, salt and
simple sugars are helpful for the people with the meta-
bolic syndrome and can improve all components of the
syndrome.26–29
Sleep patterns
Meta-analyses suggest that poor sleep duration is a
potential risk factor for the metabolic syndrome.30
Experimental studies support associations between
short-term sleep deprivation and physiological changes
related to individual metabolic syndrome components
such as weight gain, insulin resistance and elevated noc-
turnal blood pressure. Obstructive sleep apnoea is asso-
ciated with increased cardiovascular disease.31
Although it was previously assumed that this was due
to its relation with obesity, recent data suggest that
sleep apnoea is independently associated with the car-
diovascular risk factors that comprise metabolic syn-
drome, including hypertension, insulin resistance,
impaired glucose tolerance and dyslipidaemia.32 There
are multiple mechanistic pathways involved in the inter-
action between obstructive sleep apnoea, obesity and
metabolic derangements.
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Chronic inflammation
Several studies on the association between metabolic
syndrome and C-reactive protein (CRP) have been
reported. Several studies have reported that proinﬂam-
matory cytokines, such as interleukin-6, tumour necro-
sis factor-a and several others, play important roles in
the relation between metabolic syndrome and cardio-
vascular disease.33 A chronic inﬂammatory process is
known to play an important role in the pathogenesis of
atherosclerosis.34,35 Thus, obesity or metabolic syn-
drome could inﬂuence the development or progression
of atherosclerosis and with CRP being involved in this
process. Adipokines are considered to be directly linked
to pathologies associated with obesity, particularly
insulin resistance and the metabolic syndrome. White
adipose tissue may be the main site of chronic inﬂam-
mation in obesity. It is the source of increased circulat-
ing levels of inﬂammatory markers reﬂecting spill-over
from an inﬂamed tissue. Adipose tissue contributes to
the inﬂammatory pathways through the release of pro-
inﬂammatory adipokines such as leptin and chemerin
and dysregulation of anti-inﬂammatory adiponectin.
Circulating inﬂammatory biomarkers including CRP,
ﬁbrinogen, serum amyloid A, cytokines and chemo-
kines derived from monocytes are also altered and pro-
mote inﬂammation and insulin resistance. It is still
unclear to what extent inﬂammatory markers are
directly linked with the metabolic syndrome and, in
addition, with cardiovascular disease, and to what
extent they are side products of an ongoing patho-
logical process. At the moment their clinical utility is
unclear, although CRP is used in various ways in clin-
ical routine, although not to diagnose the metabolic
syndrome.
Foetal and neonatal programming
Foetal and neonatal programming can increase the risk
for future diseases and are an example of phenotypic
plasticity seen throughout nature. For instance, infants
born with low birth weight, as a marker of an
unfavourable intrauterine environment, are pro-
grammed diﬀerently and may run an increased risk
for multiple diseases, especially cardio-metabolic ones,
in adulthood. This was ﬁrst pointed out in the 1980s by
Barker et al. in the UK.36 Early catch-up growth, that
is, adiposity rebound of infants born small, will further
increase the risk of metabolic disturbances.37
Circadian rhythm
Recently, increasing interest has focused on the involve-
ment of the circadian system, a major regulator of
many aspects of metabolism and endocrine function.
Eﬀects of the circadian rhythm have been implicated
in several chronic diseases, including T2D and cardio-
vascular disease.38 While the circadian phenomenon
has been known for many body functions, there is
now increasing evidence connecting disturbances in cir-
cadian rhythm with the key components of the meta-
bolic syndrome: blood pressure, blood lipids, blood
glucose and adipose tissue. Moreover, such disturb-
ances have been found to be associated with several
comorbidities of the metabolic syndrome. including
sleep disturbances, depression, steatohepatitis and cog-
nitive impairment. In a recent publication Zimmet
et al.39 proposed that circadian disruption may be an
important underlying aetiological factor for the meta-
bolic syndrome and suggest that it be renamed the
‘circadian syndrome’.
Clinical implications of the metabolic
syndrome
Cardiovascular risk
Two Finnish studies were the ﬁrst to evaluate the
impact of the metabolic syndrome on cardiovascular
disease and mortality using either WHO or ATP III
criteria. Lakka et al.,14 using both criteria, showed
that middle-aged men with the metabolic syndrome
were at greater risk for coronary heart disease death,
cardiovascular death and total mortality than those
without (Figure 1). Likewise Isomaa et al.40 showed a
higher cardiovascular disease and total mortality in
Finnish and Swedish adults with the metabolic syn-
drome than those without according to the WHO
deﬁnition.
These early reports have been cited as proof that the
concept of the metabolic syndrome was useful for diag-
nosis and treatment. Using the US National Health and
Nutrition Examination Survey (NHANES) data Malik
et al.41 studied the impact of the metabolic syndrome
on coronary heart disease, cardiovascular disease and
overall mortality in a representative sample of adults.
These endpoints were all signiﬁcantly higher in people
with than in those without the metabolic syndrome.
The metabolic syndrome was a better predictor of car-
diovascular disease and total mortality than its individ-
ual components. The prevalence of the syndrome was
26%. In a previous analysis of the same NHANES data
the prevalence increased from 7% among participants
aged 20–29 years to 44% and 42% for participants
aged 60–69 years and 70 years, respectively.42
In 2005 Ford carried out a meta-analysis to estimate
the impact of the ATP III and WHO deﬁnitions of the
metabolic syndrome on all-cause mortality, cardiovas-
cular disease and T2D as reported in prospective
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samples of the general population.43 The relative risks
for both all-cause mortality (1.27–1.37) and cardiovas-
cular disease (1.65–1.93) were statistically signiﬁcant
and similar for both deﬁnitions of the syndrome. He
also estimated that the population-attributable risk
(PAR) fraction for the metabolic syndrome was 6–7%
for all-cause mortality and 12–17% for cardiovascular
disease. A European collaborative study included
11 cohort studies on adults without diabetes aged
from 30 to 89 years with a median follow-up of 8.8
years.44 The metabolic syndrome was diagnosed by a
modiﬁed WHO deﬁnition: hyperinsulinaemia and two
or more of obesity, hypertension, dyslipidaemia or
impaired glucose regulation. The age-standardized
prevalence of the metabolic syndrome was 16% in
men and 14% in women. The adjusted (age, serum
cholesterol and smoking) hazard ratios for all-cause
and cardiovascular mortality in persons with compared
with those without the metabolic syndrome were 1.44
and 2.26 in men and 1.38 and 2.78 in women
respectively.
Attempts have been made to compare the predictive
ability of the metabolic syndrome for cardiovascular
disease with the Framingham Risk Score (FRS).45
The metabolic syndrome did not improve the risk pre-
diction beyond that achieved by the FRS in some stu-
dies46,47 while one study reported that the metabolic
syndrome was a signiﬁcant predictor of cardiovascular
disease even after FRS adjustment.48 In the
INTERHEART study (N¼ 26,903) involving 52 coun-
tries the metabolic syndrome was associated with 2.2-to
2.7-fold increased risk of myocardial infarction. The
associations were directionally similar across all regions
and ethnic groups.49 The authors emphasized that
dichotomizing risk factors that are continuous variables
underestimates risk and decreases the magnitude of the
association.
The presence of the metabolic syndrome, in people
with or without diabetes, also increases risk for
ischaemic stroke or transient ischaemic attacks.50
A meta-analysis suggested that women with the meta-
bolic syndrome were more sensitive (relative risk (RR)
1.83) than men (RR 1.47), and that people with
the metabolic syndrome had a signiﬁcantly higher risk
of ischaemic (RR 2.12) than of haemorrhagic stroke
(RR 1.48).51
T2D risk
Early studies assessed the risk of developing T2D
among people with the metabolic syndrome deﬁned
according to the National Cholesterol Education
Program or WHO criteria.52–55 The estimated RR
was 3–6, that is, higher than that for cardiovascular
disease. In the meta-analysis by Ford.43 the PAR frac-
tion for the metabolic syndrome to develop T2D was
30–52%.
Dementia risk
A recent meta-analysis included reports from 12 studies
(N¼ 6865) aiming at quantifying the risk of progression
from mild cognitive impairment (MCI) to frank demen-
tia in people with and without T2D, and with and with-
out the metabolic syndrome.56 The overall unadjusted
pooled odds ratio for the progression of MCI to
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Figure 1. Mortality in Finnish men with and without the metabolic syndrome, aged 42 to 60 years at start of follow-up.
RR: relative risk; CI: confidence interval.
Source: adapted and reproduced with permission from American Medical Association, 2019.14
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dementia in people with T2D/metabolic syndrome was
1.67 and the pooled odds ratio for progression in
T2DþMCI 1.53 while it was 2.95 in people with the
metabolic syndromeþMCI. Thus, T2D and the meta-
bolic syndrome were both associated with an increased
incidence of dementia when co-existing with MCI.
Managing the metabolic syndrome
The importance of a healthy lifestyle for the prevention
of pre-diabetes and T2D is well established and the
evidence is stronger than that for primary prevention
of cardiovascular disease based on lifestyle modiﬁca-
tions alone. The most important studies to show bene-
ﬁts for prevention of T2D are the Da Qing Study in
China,57,58 the Malmo¨ Feasibility Study in Sweden,59
the Diabetes Prevention Study in Finland,60 and the
Diabetes Prevention Program in the USA.61 The most
important lifestyle study for primary prevention of car-
diovascular disease is the Spanish Prevencio´n con Dieta
Mediterra´nea (PREDIMED) study.62 These studies will
be brieﬂy reviewed, as well as meta-analyses that apply.
In addition some new perspective will be introduced
together with some remarks regarding the balance
between individual approaches and structural (non-
individualized) strategies to counteract the
development of cardiometabolic disease and T2D in
individuals and populations. More recently the molecu-
lar mechanisms behind the beneﬁts of exercise training
have been described, strengthening the importance of
this mode of intervention in patients with the metabolic
syndrome or T2D.63
The Da Qing study
This cluster-randomized trial, which started in 1986,
engaged 33 clinics in Da Qing, China. They were ran-
domly assigned to either serve as a control clinic or to
provide one of three interventions, diet, exercise or diet
plus exercise, during six years. The trial recruited 577
adults with impaired glucose tolerance (IGT).57 After
the six active study years the participants were fol-
lowed for up to 30 years to assess the eﬀects of
intervention on the incidence of T2D, cardiovascular
events, a composite of microvascular complications,
cardiovascular death, all-cause mortality and life
expectancy. Of the 577 participants, 438 were assigned
to one of the intervention groups and 138 to the control
group. A total of 540 (94%) of the participants were
assessed after 30 years. When compared with the con-
trol group participants in the combined intervention
group had a median delay in the onset of T2D of
3.96 years (95% conﬁdence interval (CI): 1.25–6.67;
p¼ 0.0042), fewer cardiovascular events (hazard ratio
0.74), a lower incidence of microvascular complications
(hazard ratio 0.65) and fewer cardiovascular (hazard
ratio 0.67) and all-cause deaths (hazard ratio 0.74).
Their average increase in life expectancy was 1.44
years.58 The authors concluded that this lifestyle inter-
vention in people with IGT delayed the onset of T2D
and reduced the incidence of cardiovascular events. An
important lesson is that an initial lifestyle programme
should be sustained over a long period (Figure 2).
The Malmo¨ feasibility study
From a screening programme of 6956 men (47–49 years
old) from Malmo¨, Sweden, 41 with early-stage T2D and
181 with IGT detected by means of an oral glucose toler-
ance test were selected for a prospective, non-randomized
study. The objective was to test the feasibility of a long-
term intervention with an emphasis on lifestyle changes
including dietary treatment and/or increase of physical
activity or training with annual check-ups.59 The study
was completed by 90% of subjects. Body weight was
reduced by 2.3–3.7% among participants while it
increased by 0.5–1.7% in non-intervened men with IGT
and in normal control subjects (p< 0.0001). Glucose tol-
erancewas normalized in>50%of subjects with IGT and
blood pressure, lipids and hyperinsulinaemia were
reduced. The improvement in glucose tolerance was
correlated to weight reduction and increased physical
ﬁtness. The authors concluded that the treatment was
safe and that mortality was 33% lower than in the
background cohort.59
The Diabetes Prevention Study
In Finland, 522 middle-aged, overweight persons
(women 67%; mean age 55 years; mean BMI
31 kg/m2) with IGT were randomized to either an inter-
vention or a control group.60 Each subject in the inter-
vention group received individualized counselling
aimed at reducing weight, diminishing the total intake
of fat and reducing saturated fat, increasing the intake
of ﬁbre and promoting physical activity. The mean
duration of follow-up was 3.2 years. The cumulative
incidence of T2D after four years was 11% (95% CI
6–15) in the intervention group and 23% (95% CI
17–29) in the control group. During the trial, the risk
to develop T2D was reduced by 58% (p< 0.001) in the
intervention group. This reduction was directly asso-
ciated with changes in lifestyle.
The Diabetes Prevention Program
In the USA, a total of 3234 persons free from T2D (68%
women; mean age 51 years; mean BMI 34.0 kg/m2) but
with elevated fasting and post-load plasma glucose
concentrations were randomized to placebo, metformin
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(850mgb.i.d.), or a lifestyle-modiﬁcation programme tar-
geting a weight loss 7% and 150min of weekly phys-
ical activity.61 After an average follow-up of 2.8 years the
T2D incidence was 11.0, 7.8, and 4.8/100 person-years in
the placebo, metformin and lifestyle groups, respectively.
Accordingly, the lifestyle intervention was the most
eﬃcient, reducing the incidence by 58% (95% CI
48–66) compared with 31% with metformin. During
a period of three years this translates to a number
needed to treat of 6.9 to prevent one case of T2D with
lifestyle-intervention compared with 13.9 for
metformin.61
Figure 2. Development of diabetes (a), cardiovascular events (b), microvascular events (c), cardiovascular mortality (d) and total
mortality (e) during 30 years of follow-up in the Da Qing trial.
Both mortality types decreased by lifestyle intervention in patients with impaired glucose tolerance at baseline. Noteworthy is the
rather long time it takes until the benefit in mortality starts to develop.
HR: hazard ratio; CI: confidence interval; CVD: cardiovascular disease.
Source: reproduced with permission from Elsevier, 2019.58
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The PREDIMED study
This primary preventive study randomized 7447
middle-aged subjects free from cardiovascular disease
to either an intensiﬁed Mediterranean diet, with extra
olive oil or extra nuts, or to a standard diet.62 After a
median follow-up of 4.8 years the risk of incident car-
diovascular events was signiﬁcantly reduced in the
intervention group without any diﬀerence between par-
ticipants given extra olive oil or extra nuts. In the inten-
tion-to-treat analysis including all the participants and
adjusting for baseline characteristics and propensity
scores, the hazard ratio was 0.69 (95% CI 0.53–0.91)
for a Mediterranean diet with extra-virgin olive oil and
0.72 (95% CI 0.54– 0.95) for a Mediterranean diet with
nuts compared with the standard diet.
Meta-analyses report evidence for interventions
A number of systematic reviews and meta-analyses,
built on diﬀerent designs and time frames, support life-
style interventions based on dietary changes, weight
control and physical activity for prevention of
T2D.64–73 In one of the most recent Haw et al.71
pooled 43 studies (participants 49,029; mean age
57.3 years; women 52%). Nineteen of these studies
tested medications, 19 lifestyle modiﬁcation, and ﬁve
lifestyle modiﬁcation in combination with medications.
At the end of the active intervention (range 0.5–6.3
years) lifestyle modiﬁcation was associated with a RR
reduction for T2D of 39% (RR 0.6; 95% CI 0.54–0.68)
and medications with an RR reduction of 36% (RR
0.64; 95% CI 0.54–0.76). The authors concluded that
in adults at risk for T2D, lifestyle modiﬁcation and
medications (weight loss and insulin-sensitizing
agents) successfully reduced the future incidence. The
eﬀects of medication were short lived while the lifestyle
modiﬁcation interventions were sustained for several
years.71
This message is further strengthened by data from an
intervention study aimed at weight loss and reversal of
early T2D in overweight/obese subjects, the Diabetes
Remission Clinical Trial.74 Furthermore, according to
recent ﬁndings in the Whitehall II observational study
of civil servants in London, the reversal of pre-diabetes
was also associated with a lowered cardiovascular risk
during long-term follow-up.75
However, critical voices have been raised arguing that
the currently available screening methods for dysglycae-
mia, based on fasting plasma glucose, post-challenge
glucose, or HbA1c, are imprecise and that the interven-
tion oﬀered does not reach the right people, with
questionable long-term eﬀects.76 Instead more
‘upstream’ (societal) interventions are called for such
as taxation and healthy food programmes as proposed
by the WHO.77
New perspectives on diabetes prevention
Low birth weight
In a life course perspective it is very relevant to consider
the early life predictors and opportunities for prevention
of cardiometabolic disease and T2D.78 Low birth weight
and impaired foetal growth, often resulting in small-for-
gestational-age babies, have been linked to increased
risk of hypertension, cardiovascular disease and T2D
in adult life. Thus, preventive maternal and child
health care starting already in the pre- and post-concep-
tional periods could have long term beneﬁcial
consequences. A healthy lifestyle and appropriate
dietary intake of vitamins, for example, folic acid, and
nutrients in young women may improve the chances for
a healthy embryonal and foetal development.79 This
should be followed by avoidance of smoking and alcohol
consumption during pregnancy, and encouragement of
breast feeding in the post-natal period. The weight tra-
jectories of young children have been studied and linked
to the development of cardiometabolic disease. This is
especially relevant for the so called mis-match concept80
when small-for-gestational-age babies grow too rapidly
in early post-natal life (‘catch-up growth’) that could
eventually over-stretch the biological capacities of
inner organs, with resulting beta-cell impairment in insu-
lin secretion in adult life if the subjects becomes obese
and sedentary, causing insulin resistance, at elevated risk
for T2D. This means that an appropriate diet and regu-
lar physical activity in children and adolescents could
positively contribute to a normal bodily development
(weight trajectories) and decrease the risk of
cardiometabolic problems in adult life.
Gastrointestinal microbiota
Another emerging ﬁeld of interest is the interaction
between dietary intake, genetic set-up and the gastro-
intestinal microbiota patterns for development of
T2D.81 Adult subjects with obesity or features of the
metabolic syndrome, for example, hypertension, have
been shown to have less bacterial diversity in the
gastrointestinal tract with a relative lack of healthy
and predominance of less healthy bacterial strains.82,83
As microbiota patterns are ﬁrst programmed at birth
and in early life, this opens another opportunity for
promoting healthy diet in young people, including
breastfeeding in the new born.
Subjects at increased genetic risk benefit from
healthy lifestyle
The rapidly developing knowledge of genetic factors
inﬂuencing cardiometabolic disease risk has provided
new insights in the genetic architecture behind T2D,
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both for more common and less common (rare) vari-
ants based on genome-wide association study and
exome sequencing.84 The same is true for hypertension,
obesity and coronary heart disease. This should, how-
ever, not distract the interest in lifestyle improvements
as part of prevention. In fact, recent studies have shown
that subjects at high genetic risk can modify their risk
by practising a healthy lifestyle.85 Therefore, genetic
information of high risk should encourage healthy life-
style habits even more and not lead to fatalism or even
depression.
Need for both individual and structural interventions
One critical view on the individualization of preventive
measures for patients at risk is that this has not always
been well adapted for people with less education,
adverse social background or other detrimental factors
that could distract from ﬁnding time and motivation
for improving their individual lifestyle. Therefore
more structural and societal changes are needed to
facilitate primary prevention of cardiovascular disease
and T2D.86 Examples are taxation, food labelling, city
planning, social reforms, health literacy, et cetera. As
the epidemics of obesity, malnutrition and environmen-
tal problems act synergistically for a so called global
syndemic,87 only social reforms and political decisions
can be eﬀective at a population and public health level.
This should not distract the attention of physicians,
nurses and health counselling advisors from their indi-
vidual patients, but inform them about the importance
and primacy of structural perspectives. This also
applies to families at high cardiometabolic and T2D
risk where early screening and prevention of risk
could be oﬀered,88 being of special relevance for the
prevention of T2D.89
The consultation as the basis for successful
prevention
All our evidence-based knowledge will count for noth-
ing if we cannot build trust with and reach the patient
in need of preventive measures for cardiometabolic
health. It is of great importance to ﬁnd the ﬁne balance
between giving alarming information about risk on one
side and showing a hopeful and reassuring attitude on
the other.90 In this perspective, one should remember
the words of Sir William Osler (1849–1919): ‘Ask not
what disease the person has, but rather what person the
disease has’.
The ﬁrst step in the consultation is to get to know
each other and build trust and a working alliance.
Knowledge transfer comes thereafter and should not
be unidirectional. The physician, nurse or health coun-
selling staﬀ are the experts on the medical aspects, but
the patient is the expert on his/her own personal his-
tory, bodily experiences, symptoms and worries. One
starting point could be to ask the patient what he or
she is afraid of in relation to cardiometabolic health,
often mirrored by family history and early onset of such
disorders in close relatives. The knowledge transfer of
how the body works and how risk factors act should be
accompanied by continuous trust building and motiv-
ation. In complex situations with a mix of biological
risk factors, adverse social conditions and unhealthy
lifestyle, everything cannot be changed at once. It is
better to aim for small steps that are lasting than
large, unsustainable steps with relapses of unhealthy
behaviours.91 Often a supportive spouse or family net-
work is the success factor to recognize and build upon.
Feedback and encouragement is standard. Even if the
physician has developed a plan (agenda) for the lifestyle
improvements and risk factor control there will be
relapses, disappointments and need of a new start.
Some individuals are even in denial or suspicious of
the lifestyle advice provided, they may have their own
odd ideas about, for example, dietary requirements or
the imagined perils of physical activity. In such cases
one should, if the patient prefers, encourage a second
opinion via consultation with other experts, hopefully
giving the same health message. In other cases there is a
fatalistic attitude toward health issues. This is a coping
mechanism in people with a low trust in the society, the
medical profession or in those who are victims of
oppressing social circumstances with a very limited
degree of freedom to make rational choices. The ﬁrst
step should be to apply an empathetic and listening
attitude. After further visits and trust building, the
patient may look diﬀerently at the existing health
issues.
Sometimes it is easier to add a healthy habit than to
immediately get rid of an unhealthy one, as shown in a
study on cardiac rehabilitation.92 Therefore the profes-
sional could recommend the addition of some healthy
diet components or daily walks, instead of banning bad
habits in the ﬁrst place. With time the patient may real-
ize that he or she feels better and will be more willing to
abandon the bad habits.
A sensitive question is whether ﬁnancial incentives
can be used to promote healthy lifestyle in at risk
patients. This has been tried in so called quit-and-win
campaigns for smoking cessation, with varying
results,93 even including paying a sum to high-risk
patients to quit their tobacco habit.94 The counterargu-
ment is that this is not a long-lasting eﬀect and ethically
doubtful. However, there are unexplored models that
could be of some importance. We know for example
that childhood obesity tracks in families and that
many obese children, but not all, will end up as obese
adolescents and young adults with an increased risk for
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the metabolic syndrome. A possibility would be a ran-
domized trial to evaluate paying parents a ﬁxed sum to
make sure their obese 5–7-year-old children are attend-
ing sports activities or classes to increase physical activ-
ity three times a week. If this could last for two to three
years, the incentive could then stop in the hope that
such healthy habits formed during early years could
be lasting.
Concluding remarks
A cluster of metabolic factors exists that were harmo-
nized into a deﬁnition of the metabolic syndrome in
2009. The metabolic syndrome predicts cardiovascular
disease and T2D. The risk associated with the meta-
bolic syndrome does not exceed its components,
whereof elevated blood pressure is the most frequent.
A successful management should, however, address all
factors involved. The management is always based on
healthy lifestyle choices but has frequently to be sup-
ported by pharmacological treatment, especially by
means of blood pressure lowering drugs. The metabolic
syndrome is a useful example of the importance of mul-
tiple targets for preventive interventions. A person with
the metabolic syndrome will always be aﬄicted with its
components, which is the reason that management has
to be sustained over a very long time. Drug treatment
for the components of the syndrome has to be pre-
scribed on an individual basis, and frail elderly people
should not be over-treated.
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